Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amwill Health CareBOM:544353 +1.18%42 Altman Z-Score is 10.88 as of Aug. 04, 2026, which is 53% below its 10-year median of 23.24. GuruFocus rates BOM:544353 with a GF Score™ of 42/100. The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, Amwill Health Care ranks better than 94.12% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 10.84 is strong.
Amwill Health Care has a Altman Z-Score of 10.88, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Amwill Health Care's Altman Z-Score or its related term are showing as below:
BOM:544353'
s Altman Z-Score Range Over the Past 10 Years
Min: 8.11 Med: 23.24 Max: 38.36
Current: 10.84
During the past 6 years, Amwill Health Care's highest Altman Z-Score was 38.36. The lowest was 8.11. And the median was 23.24.
Amwill Health Care (BOM:544353) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Amwill Health Care Altman Z-Score Related Terms
Amwill Health Care Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Amwill Health Care's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544353 vs MCK, COR, CAH: Altman Z-Score Comparison
For the Medical Distribution subindustry, Amwill Health Care's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amwill Health Care Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Amwill Health Care's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Amwill Health Care's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Amwill Health Care's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7616
+
1.4
*
0.2736
+
3.3
*
0.1773
+
0.6
*
14.118
+
1.0
*
0.5249
=
10.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Amwill Health Care (BOM:544353) has a Altman Z-Score of 10.88 as of Aug. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Amwill Health Care and its competitors. This is 53% below median its historical median of 23.24. Over the past decade, Amwill Health Care's Altman Z-Score has ranged from 8.11 to 38.36. According to the industry distribution chart, Amwill Health Care ranks #7 out of 119 companies in the Medical Distribution industry, placing it in the top 5.9%.
Is Amwill Health Care's Altman Z-Score too high?
Amwill Health Care's current Altman Z-Score of 10.88 is 53% below median its 10-year median of 23.24. Over the past 10 years, this metric has ranged from a low of 8.11 to a high of 38.36. The Medical Distribution industry median Altman Z-Score is 2.59. Amwill Health Care's value of 10.88 is 320.1% above this industry median. Based on the distribution chart, Amwill Health Care ranks #7 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Amwill Health Care has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Amwill Health Care's Altman Z-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Amwill Health Care ranks #7 out of 119 companies for Altman Z-Score. This places Amwill Health Care in the top 6% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.59. Amwill Health Care's value of 10.88 is 320.1% above this benchmark. Historically, Amwill Health Care's own Altman Z-Score has ranged from 8.11 to 38.36 over the past decade. While the company's 10-year median is 23.24 vs. the industry median of 2.59, Amwill Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.59, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amwill Health Care's current Altman Z-Score of 10.88 is 320.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Amwill Health Care and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amwill Health Care's current Altman Z-Score is 10.88, which is 53% below median its own 10-year median of 23.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amwill Health Care stock overvalued right now?
Amwill Health Care (BOM:544353) has a current Altman Z-Score of 10.88. The current Altman Z-Score is 10.88, which is 53% below median its 10-year median of 23.24 and 320.1% above the Medical Distribution industry median of 2.59. Amwill Health Care's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Amwill Health Care (BOM:544353), the current Altman Z-Score is 10.88 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amwill Health Care Ltd is a derma-cosmetic development company. Its focus is on development of problem solving dermatological, cosmeceutical and aesthetical products. The product portfolio is divided into two categories, namely, development and contract manufacturing of generic dermatological solutions; and developing and formulating solutions to specific The company operates in only one segment which is dealing in pharma products.
42GF Score
Get the complete analysis for BOM:544353
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544353 has been successfully added to your 
